Biocompatible peritoneal dialysis fluids: Clinical outcomes

International Journal of Nephrology

Volumn 2012, Issue , 2012, Pages

  Cho, Yeoungjee ^a   Badve, Sunil V ^a   Hawley, Carmel M ^a   Wiggins, Kathryn ^b   Johnson, David W ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84871848191     PISSN: 2090214X     EISSN: 20902158     Source Type: Journal    
DOI: 10.1155/2012/812609     Document Type: Review

References (75)

1. Davies S. J., Van Biesen W., Nicholas J., Lameire N., Integrated care. Peritoneal Dialysis International 2001 21 Supplement 3 S269 S274 2-s2.0-0035568834 (Pubitemid 34406816)
2. McDonald S. P., Marshall M. R., Johnson D. W., Polkinghorne K. R., Relationship between dialysis modality and mortality. Journal of the American Society of Nephrology 2009 20 1 155 163 2-s2.0-58149523217 10.1681/ASN. 2007111188
3. Blake P. G., Integrated end-stage renal disease care: the role of peritoneal dialysis. Nephrology Dialysis Transplantation 2001 16 Supplement 5 61 66 2-s2.0-0034874295 (Pubitemid 32750432)
4. Brown F. G., Dent A. H., Hurst K., McDonald S., Peritoneal Dialysis 2011 Australia & New Zealand Dialysis & Transplantation (ANZDATA) Registry Chapter 6
5. Boudville N., Kemp A., Clayton P., Recent peritonitis associates with mortality among patients treated with peritoneal dialysis. Journal of the American Society of Nephrology 2012 23 8 1398 1405 10.1681/ASN.2011121135
6. Catalan M. P., Santamaría B., Reyero A., Ortiz A., Egido J., Ortiz A., 3,4-Di-deoxyglucosone-3-ene promotes leukocyte apoptosis. Kidney International 2005 68 3 1303 1311 2-s2.0-30944457299 10.1111/j.1523-1755.2005. 00528.x (Pubitemid 43246451)
7. Topley N., Mackenzie R., Petersen M. M., Beavis M. J., Williams D., Thomas Faict N. D., Peluso F., Coles G. A., Davies M., Williams J. D., In vitro testing of a potentially biocompatible continuous ambulatory peritoneal dialysis fluid. Nephrology Dialysis Transplantation 1991 6 8 574 581 2-s2.0-0025776459
8. Witowski J., Topley N., Jorres A., Liberek T., Coles G. A., Williams J. D., Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis. Kidney International 1995 47 1 282 293 2-s2.0-0028950696
9. Mortier S., De Vriese A. S., McLoughlin R. M., Topley N., Schaub T. P., Passlick-Deetjen J., Lameire N. H., Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane. Journal of the American Society of Nephrology 2003 14 5 1296 1306 2-s2.0-0037407760 10.1097/01.ASN.0000060681.91079.30 (Pubitemid 36514669)
10. Boulanger E., Wautier M. P., Wautier J. L., Boval B., Panis Y., Wernert N., Danze P. M., Dequiedt P., AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney International 2002 61 1 148 156 2-s2.0-0036147232 10.1046/j.1523-1755.2002.00115.x (Pubitemid 34075141)
11. Schambye H. T., Effect of different buffers on the biocompatibility of CAPD solutions. Peritoneal Dialysis International 1996 16 Supplement 1 S130 S136 2-s2.0-0029953197 (Pubitemid 26159727)
12. Mortier S., De Vriese A. S., Lameire N., Recent concepts in the molecular biology of the peritoneal membrane-implications for more biocompatible dialysis solutions. Blood Purification 2003 21 1 14 23 2-s2.0-0037261185 10.1159/000067867 (Pubitemid 36173343)
13. Williams J. D., Craig K. J., Topley N., Von Ruhland C., Fallon M., Newman G. R., Mackenzie R. K., Williams G. T., Morphologic changes in the peritoneal membrane of patients with renal disease. Journal of the American Society of Nephrology 2002 13 2 470 479 2-s2.0-0036158071 (Pubitemid 34106290)
14. Mactier R. A., Sprosen T. S., Gokal R., Williams P. F., Lindbergh M., Naik R. B., Wrege U., Gröntoft K. C., Larsson R., Berglund J., Tranæus A. P., Faict D., Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney International 1998 53 4 1061 1067 2-s2.0-15644368482 10.1111/j.1523-1755.1998.00849.x (Pubitemid 28155684)
15. Justo P., Sanz A. B., Egido J., Ortiz A., 3,4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells. Diabetes 2005 54 8 2424 2429 2-s2.0-23644433184 10.2337/diabetes.54.8.2424 (Pubitemid 41134271)
16. Tanikawa T., Okada Y., Tanikawa R., Tanaka Y., Advanced glycation end products induce calcification of vascular smooth muscle cells through rage/p38 MAPK. Journal of Vascular Research 2009 46 6 572 580 2-s2.0-67649447069 10.1159/000226225
17. Fusshoeller A., Plail M., Grabensee B., Plum J., Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study. Nephrology Dialysis Transplantation 2004 19 8 2101 2106 2-s2.0-4344679569 10.1093/ndt/gfh326 (Pubitemid 39139644)
18. Topley N., In vitro biocompatibility of bicarbonate-based peritoneal dialysis solutions. Peritoneal Dialysis International 1997 17 1 42 47 2-s2.0-0030691943 (Pubitemid 27475046)
19. Mortier S., Lameire N. H., De Vriese A. S., The effects of peritoneal dialysis solutions on peritoneal host defense. Peritoneal Dialysis International 2004 24 2 123 138 2-s2.0-1942422567 (Pubitemid 38515076)
20. Mortier S., Faict D., Schalkwijk C. G., Lameire N. H., De Vriese A. S., Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney International 2004 66 3 1257 1265 2-s2.0-4344696765 10.1111/j.1523-1755.2004.00879.x (Pubitemid 39121036)
21. Witowski J., Wisniewska J., Korybalska K., Bender T. O., Breborowicz A., Gahl G. M., Frei U., Passlick-Deetjen J., Jörres A., Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. Journal of the American Society of Nephrology 2001 12 11 2434 2441 2-s2.0-0034752646 (Pubitemid 33021121)
22. Passlick-Deetjen J., Lage C., Lactate-buffered and bicarbonate-buffered solutions with less glucose degradation products in a two-chamber system. Peritoneal Dialysis International 2000 20 Supplement 2 S42 S47 2-s2.0-0034044155 (Pubitemid 30410555)
23. Devuyst O., Topley N., Williams J. D., Morphological and functional changes in the dialysed peritoneal cavity: impact of more biocompatible solutions. Nephrology Dialysis Transplantation 2002 17 Supplement 3 12 15 2-s2.0-0036242468 (Pubitemid 34450111)
24. Mackenzie R., Holmes C. J., Jones S., Williams J. D., Topley N., Clinical indices of in vivo biocompatibility: the role of ex vivo cell function studies and effluent markers in peritoneal dialysis patients. Kidney International 2003 64 88 S84 S93 2-s2.0-0344011072 (Pubitemid 37452817)
25. Mortier S., Faict D., Lameire N. H., De Vriese A. S., Benefits of switching from a conventional to a low-GDP bicarbonate/lactate- buffered dialysis solution in a rat model. Kidney International 2005 67 4 1559 1565 2-s2.0-16244382350 10.1111/j.1523-1755.2005.00237.x (Pubitemid 40463136)
26. Furkert J. D., Zeier M., Schwenger V., Effects of Peritoneal dialysis solutions low in GDPs on peritonitis and exit-site infection rates. Peritoneal Dialysis International 2008 28 6 637 640 2-s2.0-60249095758
27. Lee H. Y., Park H. C., Seo B. J., Do J. Y., Yun S. R., Song H. Y., Kim Y. H., Kim Y. L., Kim D. J., Kim Y. S., Ahn C., Kim M. J., Shin S. K., Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (balance). Peritoneal Dialysis International 2005 25 3 248 255 2-s2.0-21144438457 (Pubitemid 40724205)
28. Stankovic-Popovic V., Effects of conventional versus biocompatible peritoneal dialysis solutions on peritoneal and systemic inflammation, malnutrition and atherosclerosis in CAPD patients. Clinical Nephrology 2011 76 4 314 322
29. Bargman J. M., Thorpe K. E., Churchill D. N., Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. Journal of the American Society of Nephrology 2001 12 10 2158 2162 2-s2.0-0034823268 (Pubitemid 32880353)
30. Bajo M. A., Príez-Lozano M. L., Albar-Vizcaino P., Del Peso G., Castro M. J., Gonzalez-Mateo G., Fernández-Perpén A., Aguilera A., Sánchez-Villanueva R., Sánchez-Tomero J. A., López-Cabrera M., Peter M. E., Passlick-Deetjen J., Selgas R., Low-GDP peritoneal dialysis fluid ('balance') has less impact in vitro and ex vivo on epithelial-to- mesenchymal transition (EMT) of mesothelial cells than a standard fluid. Nephrology Dialysis Transplantation 2011 26 1 282 291 2-s2.0-78650633059 10.1093/ndt/gfq357
31. Choi H. Y., Kim D. K., Lee T. H., Moon S. J., Han S. H., Lee J. E., Kim B. S., Park H. C., Choi K. H., Ha S. K., Han D. S., Lee H. Y., The clinical usefulness of peritoneal dialysis fluids with neural pH and low glucose degradation product concentration: an open randomized prospective trial. Peritoneal Dialysis International 2008 28 2 174 182 2-s2.0-42349109993 (Pubitemid 351552402)
32. Fan S. L. S., Pile T., Punzalan S., Raftery M. J., Yaqoob M. M., Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney International 2008 73 2 200 206 2-s2.0-37549066703 10.1038/sj.ki.5002574
33. Fernandez-Perpén A., Pérez-Lozano M. L., Bajo M. A., Influence of Bicarbonate/Low-Gdp peritoneal dialysis fluid (Bicavera) on in vitro and ex vivo epithelial-to-mesenchymal transition of mesothelial cells. Peritoneal Dialysis International 2012 32 3 292 304 10.3747/pdi.2010.00315
34. Haag-Weber M., Krämer R., Haake R., Islam M. S., Prischl F., Haug U., Nabut J. L., Deppisch R., Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study. Nephrology Dialysis Transplantation 2010 25 7 2288 2296 2-s2.0-77954341511 10.1093/ndt/gfq087
35. Haas S., Schmitt C. P., Arbeiter K., Bonzel K. E., Fischbach M., John U., Pieper A. K., Schaub T. P., Passlick-Deetjen J., Mehls O., Schaefer F., Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis. Journal of the American Society of Nephrology 2003 14 10 2632 2638 2-s2.0-0141790160 10.1097/01.ASN.0000086475.83211.DF (Pubitemid 37169350)
36. Kim S., Oh J., Kim S., Chung W., Ahn C., Kim S. G., Oh K. H., Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. Nephrology Dialysis Transplantation 2009 24 9 2899 2908 2-s2.0-69249088031 10.1093/ndt/gfp054
37. Lai K. N., A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products. Peritoneal Dialysis International 2012 32 3 280 291 10.3747/pdi.2010.00176
38. Pajek J., Kveder R., Bren A., Guček A., Bučar M., Škoberne A., Waniewski J., Lindholm B., Short-term effects of bicarbonatelactate-buffered and conventional lactate-buffered dialysis solutions on peritoneal ultrafiltration: a comparative crossover study. Nephrology Dialysis Transplantation 2009 24 5 1617 1625 2-s2.0-65249119335 10.1093/ndt/gfn673
39. Rippe B., Simonsen O., Heimbürger O., Christensson A., Haraldsson B., Stelin G., Weiss L., Nielsen F. D., Bro S., Friedberg M., Wieslander A., Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney International 2001 59 1 348 357 2-s2.0-0035162741 10.1046/j.1523-1755.2001.00497.x (Pubitemid 32055244)
40. Szeto C., Lam C., Leung C., Kwan B., Chung K., Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products-a 1-year randomized control trial. Nephrology Dialysis Transplantation 2007 22 2 552 559 2-s2.0-33846654231 10.1093/ndt/gfl559 (Pubitemid 46189901)
41. Tranaeus A., A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution-clinical benefits. Peritoneal Dialysis International 2000 20 5 516 523 2-s2.0-0033653329
42. Weiss L., Stegmayr B., Malmsten G., Tejde M., Hadimeri H., Siegert C. E., Ahlmén J., Larsson R., Ingman B., Simonsen O., van Hamersvelt H. W., Johansson A. C., Hylander B., Mayr M., Nilsson P. H., Andersson P. O., De los Ríos T., Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution. Peritoneal Dialysis International 2009 29 6 647 655 2-s2.0-77954337529
43. Williams J. D., Topley N., Craig K. J., Mackenzie R. K., Pischetsrieder M., Lage C., Passlick-Deetjen J., The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney International 2004 66 1 408 418 2-s2.0-3042720430 10.1111/j.1523-1755. 2004.00747.x (Pubitemid 38870119)
44. Johnson D. W., Effects of Biocompatible versus standard fluid on peritoneal dialysis outcomes. Journal of the American Society of Nephrology 2012 23 6 1097 1107
45. Kim Y. L., Do J., Park S. H., Cho K., Park J., Yoon K., Cho D. K., Lee E. G., Kim I. S., Low glucose degradation products dialysis solution modulates the levels of surrogate markers of peritoneal inflammation, integrity, and angiogenesis: preliminary report. Nephrology 2003 8 Supplement s2 S28 S32 2-s2.0-0346333503 10.1046/j.1440-1797.8.s.6.x (Pubitemid 38056411)
46. Lui S. L., Yung S., Yim A., A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial. American Journal of Kidney Diseases 2012 60 6 966 975 10.1053/j.ajkd.2012.05.018
47. Feriani M., Kirchgessner J., La Greca G., Passlick-Deetjen J., Becker H., Bohler J., Brown C. B., Buoncristiani U., Di Paolo N., Gahl G. M., Gotloib L., Hylander B., Lameire N., Montenegro J., Pedersen F. B., Schollmeyer P., Selgas R., Slingeneyer A., Williams J. D., Randomized long-term evaluation of bicarbonate-buffered CAPD solution. Kidney International 1998 54 5 1731 1738 2-s2.0-7844232754 10.1046/j.1523-1755.1998.00167.x (Pubitemid 28502918)
48. Parikova A., Struijk D. G., Zweers M. M., Langedijk M., Schouten N., van den Berg N., Duis S., Krediet R. T., Does the biocompatibility of the peritoneal dialysis solution matter in assessment of peritoneal function? Peritoneal Dialysis International 2007 27 6 691 696 2-s2.0-41049103837 (Pubitemid 351843490)
49. Bargman J. M., Thorpe K. E., Churchill D. N., Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. Journal of the American Society of Nephrology 2001 12 10 2158 2162 2-s2.0-0034823268 (Pubitemid 32880353)
50. Srivastava S., Hildebrand S., Fan S. L. S., Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique survival. Kidney International 2011 80 9 986 991 2-s2.0-79960892059 10.1038/ki.2011.244
51. Kim S. G., Kim S., Hwang Y. H., Kim K., Oh J. E., Chung W., Oh K. H., Kim H. J., Ahn C., Could solutions low in glucose degradation products preserve residual renal function in incident peritoneal dialysis patients? A 1-year multicenter prospective randomized controlled trial (Balnet study). Peritoneal Dialysis International 2008 28 Supplement 3 S117 S122 2-s2.0-48749085982
52. Kim S. J., Chung W. K., Oh K. H., Kim S. G., Effect of biocompatible PD fluid on preservation of residual renal function incident CAPD patients: two-year extended follow-up study. Nephrology Dialysis Transplantation 2010 3 iii175 iii176
53. Feriani M., Krediet R. T., Khanna R., Krediet R. T., New peritoneal dialysis solutions and solutions on the horizon. Nolph and Gokal'S Textbook of Peritoneal DialySiS 2009 New York, NY, USA Springer Chapter 11
54. Lage C., Pischetsrieder M., Aufricht C., Jörres A., Schilling H., Passlick-Deetjen J., First in vitro and in vivo experiences with stay · safe balance, a pH-neutral solution in a dual-chambered bag. Peritoneal Dialysis International 2001 20 Supplement 5 S28 S32 2-s2.0-0035119578 (Pubitemid 32184349)
55. Twardowski Z. J., PET-a simpler approach for determining prescriptions for adequate dialysis therapy. Advances in Peritoneal Dialysis 1990 6 186 191 2-s2.0-0025656439
56. Fried L., Higher membrane permeability predicts poorer patient survival. Peritoneal Dialysis International 1997 17 4 387 389 2-s2.0-0030732163 (Pubitemid 27470215)
57. Rumpsfeld M., McDonald S. P., Johnson D. W., Higher peritoneal transport status is associated with higher mortality and technique failure in the Australian and New Zealand peritoneal dialysis patient populations. Journal of the American Society of Nephrology 2006 17 1 271 278 2-s2.0-33645457575 10.1681/ASN.2005050566
58. Churchill D. N., Thorpe K. E., Nolph K. D., Keshaviah P. R., Oreopoulos D. G., Pagé D., Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. Journal of the American Society of Nephrology 1998 9 7 1285 1292 2-s2.0-0031777777 (Pubitemid 28283893)
59. Wang T., Heimbürger O., Waniewski J., Bergström J., Lindholm B., Increased peritoneal permeability is associated with decreased fluid and small-solute removal and higher mortality in CAPD patients. Nephrology Dialysis Transplantation 1998 13 5 1242 1249 2-s2.0-0031979364 10.1093/ndt/13.5.1242 (Pubitemid 28227205)
60. Davies S. J., Phillips L., Russell G. I., Peritoneal solute transport predicts survival on CAPD independently of residual renal function. Nephrology Dialysis Transplantation 1998 13 4 962 968 2-s2.0-0031924486 10.1093/ndt/13.4.962 (Pubitemid 28161772)
61. Pecoits-Filho R., Stenvinkel P., Lindholm B., Heimburger O., Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Peritoneal Dialysis International 2006 26 1 53 63 2-s2.0-33745513606 (Pubitemid 44339662)
62. Oh K. H., Jung J. Y., Yoon M. O., Song A., Lee H., Ro H., Hwang Y. H., Kim D. K., Margetts P., Ahn C., Intra-peritoneal interleukin-6 system is a potent determinant of the baseline peritoneal solute transport in incident peritoneal dialysis patients. Nephrology 2010 25 5 1639 1646 2-s2.0-77955287955 10.1093/ndt/gfp670
63. Numata M., Kawakami M., Lindholm B., Nakayama M., Schepro D., Peritoneal microvessels and high peritoneal transport rate (PSTR). Microvascular Research 2006 Elsevier Science Chapter 67
64. Davies S. J., Phillips L., Naish P. F., Russell G. I., Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. Journal of the American Society of Nephrology 2001 12 5 1046 1051 2-s2.0-0035035682 (Pubitemid 32378346)
65. Fischback M., Terzic J., Chauvé S., Laugel V., Muller A., Haraldsson B., Effect of peritoneal dialysis fluid composition on peritoneal area available for exchange in children. Nephrology Dialysis Transplantation 2004 19 4 925 932 2-s2.0-1842575707 10.1093/ndt/gfg518 (Pubitemid 38455666)
66. John S. G., Selby N. M., McIntyre C. W., Effects of peritoneal dialysis fluid biocompatibility on baroreflex sensitivity. Kidney international 2008 108 S119 S124 2-s2.0-44449150757 (Pubitemid 351466528)
67. Fang W., Mullan R., Shah H., Mujais S., Bargman J. M., Oreopoulos D. G., Comparison between bicarbonate/lactate and standard lactate dialysis solution in peritoneal transport and ultrafiltration: a prospective, crossover single-dwell study. Peritoneal Dialysis International 2008 28 1 35 43 2-s2.0-42449126330 (Pubitemid 351566124)
68. Coles G. A., O'Donoghue D. J., Pritchard N., Ogg C. S., Jani F. M., Gokal R., Cancarini G. C., Maiorca R., Traæus A., De Vos C., Hopwood A., Faict D., A controlled trial of two bicarbonate-containing dialysis fluids for CAPD-final report. Nephrology Dialysis Transplantation 1998 13 12 3165 3171 2-s2.0-7844247176 (Pubitemid 28534725)
69. Rippe B., Wieslander A., Musi B., Long-term results with low glucose degradation product content in peritoneal dialysis fluids. Contributions to Nephrology 2003 140 47 55 2-s2.0-42349088242
70. Cho J. H., Hur I. K., Kim C. D., Park S. H., Ryu H. M., Yook J. M., Choi J. Y., Choi H. J., Choi H. J., Park J. W., Do J. Y., Kim Y. L., Impact of systemic and local peritoneal inflammation on peritoneal solute transport rate in new peritoneal dialysis patients: a 1-year prospective study. Nephrology Dialysis Transplantation 2010 25 6 1964 1973 2-s2.0-77953013939 10.1093/ndt/gfp767
71. Rumpsfeld M., McDonald S. P., Purdie D. M., Collins J., Johnson D. W., Predictors of Baseline Peritoneal Transport Status in Australian and New Zealand Peritoneal Dialysis Patients. American Journal of Kidney Diseases 2004 43 3 492 501 2-s2.0-1542317728 10.1053/j.ajkd.2003.11.010 (Pubitemid 38298209)
72. Davies S. J., Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney International 2004 66 6 2437 2445 2-s2.0-15044352134
73. Davies S. J., Mushahar L., Yu Z., Lambie M., Determinants of peritoneal membrane function over time. Seminars in Nephrology 2011 31 2 172 182 2-s2.0-79952780842 10.1016/j.semnephrol.2011.01.006
74. Montenegro J., Saracho R., Gallardo I., Martñnez I., Muñoz R., Quintanilla N., Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis. Nephrology Dialysis Transplantation 2007 22 6 1703 1708 2-s2.0-34447578047 10.1093/ndt/gfl848 (Pubitemid 47073772)
75. Wiggins K. J., Craig J. C., Johnson D. W., Strippoli G. F. M., Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database of Systematic Reviews 2009 1 2-s2.0-70249140543 10.1002/14651858.CD007554 CD007554